GRCE
Grace Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.10
−1.87%1
Insider buys (3m)
0
Insider sells (3m)
$24.2K
Net value (3m)
-9.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | Macdonald R. Loch · officer: Chief Medical Officer | A-Award | 54,690 | $2.12 |
| Sep 1, 2026 | Kohli Prashant · director, officer: Chief Executive Officer | A-Award | 267,160 | $2.12 |
| Sep 1, 2026 | Kumar Amresh · officer: VP Program Management | A-Award | 35,760 | $2.12 |
| Sep 1, 2026 | DelAversano Robert J · officer: Principal Financial Officer | A-Award | 33,660 | $2.12 |
| Aug 19, 2026 | Opaleye Management Inc. · 10 percent owner | Purchase | 11,608 | $2.09 |
| Jan 12, 2026 | Kavuru Vimal · director | A-Award | 10,000 | $3.80 |
| Jan 12, 2026 | Kottayil George · director | A-Award | 10,000 | $3.80 |
| Jan 12, 2026 | NEUGEBOREN EDWARD · director | A-Award | 10,000 | $3.80 |
| Jan 12, 2026 | DAVIS A BRIAN · director | A-Award | 10,000 | $3.80 |
| May 13, 2025 | Kavuru Vimal · director | A-Award | 10,000 | $2.72 |
| May 13, 2025 | DAVIS A BRIAN · director | A-Award | 10,000 | $2.72 |
| May 13, 2025 | NEUGEBOREN EDWARD · director | A-Award | 10,000 | $2.72 |
| May 13, 2025 | Kottayil George · director | A-Award | 10,000 | $2.72 |
| Apr 16, 2025 | Macdonald R. Loch · officer: Chief Medical Officer | A-Award | 40,000 | $2.08 |
| Apr 16, 2025 | Kumar Amresh · officer: VP Program Management | A-Award | 30,000 | $2.08 |
| Apr 16, 2025 | DelAversano Robert J · officer: Principal Financial Officer | A-Award | 20,130 | $2.08 |
| Apr 16, 2025 | Kohli Prashant · director, officer: Chief Executive Officer | A-Award | 225,400 | $2.08 |
| Apr 16, 2025 | D'Andrea Carrie · officer: VP Clinical Operations | A-Award | 30,000 | $2.08 |
Institutional positioning
13F filings over the trailing two quarters
New 19Increased 7Reduced 4Sold out 34
| Filer | Action | Shares | Filed |
|---|---|---|---|
| CERITY PARTNERS LLC | Increased | 849,055 | May 15, 2026 |
| EVERSEPT PARTNERS, LP | New Position | 756,600 | May 15, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Reduced | 728,203 | May 15, 2026 |
| BANK OF AMERICA CORP /DE/ | Increased | 494,723 | May 18, 2026 |
| CITADEL ADVISORS LLC | Increased | 402,240 | Sep 2, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 401,656 | May 15, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 243,910 | May 14, 2026 |
| JANE STREET GROUP, LLC | New Position | 167,097 | May 12, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | New Position | 112,800 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 98,742 | May 15, 2026 |
| MARSHALL WACE, LLP | New Position | 91,416 | May 15, 2026 |
| CONNECTIVE CAPITAL MANAGEMENT, LLC | New Position | 84,549 | May 13, 2026 |
| QUADRATURE CAPITAL LTD | New Position | 66,822 | May 15, 2026 |
| XTX TOPCO LTD | Increased | 63,094 | May 15, 2026 |
| BIRCHVIEW CAPITAL, LP | New Position | 50,000 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 1, 2026